A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder

Clinical Therapeutics

Volumn 28, Issue 2, 2006, Pages 280-293

  Biederman, Joseph ^a,b,e   Wigal, Sharon B ^b,e   Spencer, Thomas J ^a,e   McGough, James J ^c,e   Mays, David A ^d,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SHIRE   (United States)

Author keywords

Adderall XR; ADHD; amphetamine; atomoxetine; attention deficit hyperactivity disorder; girls; laboratory school study; nonstimulant; stimulant; Strattera

Indexed keywords

AMPHETAMINE; ATOMOXETINE;

ABDOMINAL PAIN; ANALYTIC METHOD; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG TOLERANCE; FATIGUE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; TITRIMETRY; WEIGHT REDUCTION;

ADRENERGIC UPTAKE INHIBITORS; AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; PROPYLAMINES; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 33646202334     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.02.008     Document Type: Article

References (32)

1. American Academy of Pediatrics. Clinical practice guideline: Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 105 (2000) 1158-1170
2. [published correction appears in J Am Acad Child Adolesc Psychiatry. 1997;36: 1783]. Gaub M., and Carlson C. Gender differences in ADHD: A meta-analysis and critical review. J Am Acad Child Adolesc Psychiatry 36 (1997) 1036-1045
3. Olfson M., Gameroff M., Marcus S., and Jensen P. National trends in the treatment of attention deficit hyperactivity disorder. Am J Psychiatry 160 (2003) 1071-1077
4. Robison L., Sclar D., Skaer T., and Galin R. Treatment modalities among US children diagnosed with attention-deficit hyperactivity disorder: 1995-99. Int Clin Psychopharmacol 19 (2004) 17-22
5. Biederman J., and Faraone S. The Massachusetts General Hospital studies of gender influences on attention-deficit/hyperactivity disorder in youth and relatives. Psychiatr Clin North Am 27 (2004) 225-232
6. Abikoff H., Jensen P., Arnold L., et al. Observed classroom behavior of children with ADHD: Relationship to gender and comorbidity. J Abnorm Child Psychol 30 (2002) 349-359
7. Biederman J., Mick E., Faraone S., et al. Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry 159 (2002) 36-42
8. Biederman J., Kwon A., Aleardi M., et al. Absence of gender effects on attention deficit hyperactivity disorder: Findings in nonreferred subjects. Am J Psychiatry 162 (2005) 1083-1089
9. Faraone S., Biederman J., Mick E., et al. Family study of girls with attention deficit hyperactivity disorder. Am J Psychiatry 157 (2000) 1077-1183
10. Carlson C., Tamm L., and Gaub M. Gender differences in children with ADHD, ODD, and co-occurring ADHD/ODD identified in a school population. J Am Acad Child Adolesc Psychiatry 36 (1997) 1706-1714
11. Graetz B., Sawyer M., and Baghurst P. Gender differences among children with DSM-IV ADHD in Australia. J Am Acad Child Adolesc Psychiatry 44 (2005) 159-168
12. Greenhill L., Pliszka S., Dulcan M., et al., for the American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41 Suppl 2 (2002) 26S-49S
13. Connors C. Forty years of methylphenidate treatment in Attention-Deficit/Hyperactivity Disorder. J Atten Disord. 6 Suppl 1 (2002) S17-S30
14. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-Month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 113 (2004) 754-761
15. Pliszka S., Browne R., Olvera R., and Wynne S. A double-blind, placebocontrolled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 39 (2000) 619-626
16. Efron D., Jarman F., and Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial. Pediatrics 100 (1997) 662-666
17. Wilens T., McBurnett K., Bukstein O., et al. Multisite, controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 160 (2006) 82-90
18. McGough J., Biederman J., Wigal S., et al. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry 44 (2005) 530-538
19. Michelson D., Allen A., Busner J., et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebocontrolled study. Am J Psychiatry 159 (2002) 1896-1901
20. Kelsey D., Sumner C., Casat C., et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebocontrolled trial. Pediatrics 114 (2004) e1-e8
21. Arnold L. Sex differences in ADHD: Conference summary. J Abnorm Child Psychol 24 (1996) 555-569
22. Wigal S., McGough J., McCracken J., et al. Analog classroom study of amphetamine and atomoxetine in youth with ADHD. Poster presented at: 157th Annual Meeting of the American Psychiatric Association. New York, NY (May 1-6, 2004)
23. Available at. World Medical Association. Declaration of Helsinki. Accessed December 27, 2005. http://www.wma.net/e/ethicsunit/Helsinki.htm
24. Diagnostic and Statistical Manual of Mental Health Disorders. Fourth Edition (2000), American Psychiatric Association, Washington, DC
25. Adderall XR [package insert] (2004), Shire US, Inc., Wayne, PA
26. Strattera [package insert] (December 2004), Eli Lilly and Company, Indianapolis, Ind
27. Wigal S., Gupta S., Guinta D., and Swanson J. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull 34 (1998) 47-53
28. for the Atomoxetine ADHD Study Group. Biederman J., Heiligenstein J., Faries D., et al. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics 110 (2002) e75
29. [published correction appears in J Child Psychol Psychiatry. 1993;34:437]. Barkley R. Hyperactive girls and boys: Stimulant drug effects on mother-child interactions. J Child Psychol Psychiatry 30 (1989) 379-390
30. Pelham Jr. W., Walker J., Sturges J., and Hoza J. Comparative effects of methylphenidate on ADD girls and ADD boys. J Am Acad Child Adolesc Psychiatry 28 (1989) 773-776
31. West S., Muniz R., Quinn P., et al. The GRACE Study: An evaluation of girls, Ritalin, and ADHD. Poster presented at: 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Washington, DC (October 19-24, 2004)
32. Sharp W., Walter J., Marsh W., et al. ADHD in girls: Clinical comparability of a research sample. J Am Acad Child Adolesc Psychiatry 38 (1999) 40-47